乳腺癌是乳腺恶性肿瘤,是全球女性发病率较高的癌症,约占女性癌症患者的20%,也是100多个国家癌症死亡的主要原因。近年来全球乳腺癌发病率一直呈上升趋势。 乳腺癌根据病理分型可分为非浸润性癌,早期浸润性癌,浸润性癌。根据分子分型可分为雌激素受体阳性乳腺癌(ER+PR+HER2-),HER2阳性乳腺癌(ER-PR-HER2+),三阴性乳腺癌(ER-PR-HER2-)。不同类型的乳腺癌,从治疗方法到预后都是非常不同,需要针对已经明确的致癌位点,探索相关靶点来设计相应的药物。 TargetMol 抗乳腺癌库收集了2440 种与乳腺癌相关的化合物,包含了已经报道的有乳腺癌治疗作用的化合物,以及相关的靶点通路(HER-2, VEGF, EGFR, PARP, CDK4/6, HSP, PD-1, SET7/9, BRCA 等),是乳腺癌药物研发的良好工具。
Empty | 99873-43-5 | 99-66-1 | 99-32-1 | 99-24-1 | 99105-77-8 | 989-51-5 | 98619-25-1 | 978-62-1 | 97682-44-5 | 97-53-0 | Empty |
Droxinostat | Valproic Acid | Chelidonic acid | Methyl gallate | Sulcotrione | (-)-Epigallocatechin Gallate | Schisandrone | IMD-0354 | Irinotecan | Eugenol | ||
Empty | 97322-87-7 | 96990-18-0 | 96017-59-3 | 959841-49-7 | 95975-55-6 | 959551-10-1 | 959-23-9 | 958852-01-2 | 95847-70-4 | 958233-07-3 | Empty |
Troglitazone | Momordin Ic | 2-hexyl-4-Pentynoic Acid | (E)-Akt inhibitor-IV | Guggulsterone | NIH-12848 | 4'-Methoxychalcone | GSK1059615 | Ipsapirone | DPA-714 | ||
Empty | 957-68-6 | 957054-33-0 | 957054-30-7 | 956958-53-5 | 955977-50-1 | 955900-27-3 | 955365-80-7 | 952021-60-2 | 951151-97-6 | 950762-95-5 | Empty |
7-Aminocephalosporanic acid | Pictilisib dimethanesulfonate | Pictilisib | Pilaralisib analogue | PI-3065 | RK-9123016 | Adavosertib | PF 477736 | JNJ-38158471 | PCI-34051 | ||
Empty | 95058-81-4 | 94987-08-3 | 94805-82-0 | 946518-60-1 | 945619-74-9 | 945189-68-4 | 944396-88-7 | 944396-07-0 | 944328-88-5 | 94-41-7 | Empty |
Gemcitabine | Gypenoside XLIX | Glycycoumarin | LY2409881 trihydrochloride | OPHIOPOGONIN D | SJ000063181 | NIBR-17 | Buparlisib | QS11 | Chalcone | ||
Empty | 943820-93-7 | 943319-70-8 | 943119-42-4 | 942918-07-2 | 942655-44-9 | 942425-68-5 | 942289-87-4 | 941575-71-9 | 939791-38-5 | 938-55-6 | Empty |
Wnt/β-catenin agonist 2 | Ponatinib | OUL232 | GSK-1070916 | JK-P3 | PHA-767491 hydrochloride | PI-828 | BIP-135 | PF-562271 besylate | 6-(Dimethylamino)purine | ||
Empty | 938440-64-3 | 93772-31-7 | 937265-83-3 | 937263-43-9 | 937174-76-0 | 937039-45-7 | 936890-98-1 | 936446-61-6 | 936345-35-6 | 936345-34-5 | Empty |
KU-0063794 | Neogambogic acid | ARRY-380 (analog ) | Tucatinib | GSK-690693 | Pimelic diphenylamide 106 | OSI-027 | NRC-2694 | PF-02413873 | Benzonitrile, 4-[[5-cyclopropyl-3-methyl-1-[(methylsulfonyl)methyl]-1H-pyrazol-4-yl]oxy]-2,6-dimethyl- | ||
Empty | 935881-37-1 | 934828-12-3 | 934826-68-3 | 934541-31-8 | 934526-89-3 | 934493-76-2 | 934389-88-5 | 934353-76-1 | 934343-74-5 | 934162-61-5 | Empty |
AR42 | CXD101 | Visomitin | TAK-901 | Pilaralisib | Voxtalisib | LY-294002 hydrochloride | ENMD-2076 | NVP-HSP990 | A-966492 | ||
Empty | 932359-76-7 | 931417-26-4 | 93117-08-9 | 93-07-2 | 930039-92-2 | 929016-96-6 | 92831-11-3 | 928037-13-2 | 927961-18-0 | 927885-00-5 | Empty |
FiVe1 | ANI-7 | 5-AIQ | Veratric acid | BRD4 Inhibitor-27 | Pracinostat | MN-64 | Golvatinib | Lanifibranor | HS-1793 |